Clinical Trial

Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo® after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent clinical study protocols.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-22.
Trial Details
NCT Number NCT07495930
Lead Sponsor Shanghai Henlius Biotech
Conditions Health Adult Subjects
Enrollment 24 participants
Start Date 2026-04-30
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-01